← Leaderboards
Nathaniel James Rhodes
Midwestern University
$3,151,448
Attributed
$3,151,448
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $934.7K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,151,448 · 2
By mechanism
R01$2,734,140 · 1
R21$417,308 · 1
Top collaborators
No co-investigators on record.
Most similar at Midwestern University
Same institution · by research overlap
- Marc Howard Scheetz$3,063,567
Others in their field
Other Rising Stars on “Intensive Care Units”
- Everardo Cobos · University Of Texas Rio Grande Valley$3,825,846
- Sebastian Tong · University Of Washington$2,998,489
- Gary Lessing · Inovodel, Inc.$2,946,822
- Michelle S Troche · Columbia University Teachers College$2,565,491
- Kellie Bickel · Twinstrand Biosciences, Inc.$2,555,383
- Kara N Goss · Ut Southwestern Medical Center$2,418,062
Research focus
Intensive Care UnitsInfrastructureIndividual PatientHealth Care CostsInfectionAlveolarDoseDrug Resistant PathogenAntibiotic ResistanceFundingAntibiotic Resistant InfectionsBiobankBronchoalveolar Lavage FluidAntibioticsAntibiotic TherapyCessation Of LifeDrug KineticsClinical EfficacyClinical ResearchClinical RiskDiagnosticCritical IllnessBeta-LactamsKlebsiella Aerogenes
Grant awards (6)
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia$669,238
R01 · FY2025 · AI · contact PI
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia$669,238
R01 · FY2024 · AI · contact PI
Development and Evaluation of CRRT-Specific Precision Dosing Models to Optimize Beta-Lactam Treatment for Patients with Hospital-Acquired Pneumonia$151,881
R21 · FY2024 · AI · contact PI
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia$669,238
R01 · FY2023 · AI · contact PI
Development and Evaluation of CRRT-Specific Precision Dosing Models to Optimize Beta-Lactam Treatment for Patients with Hospital-Acquired Pneumonia$265,427
R21 · FY2023 · AI · contact PI
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia$726,426
R01 · FY2022 · AI · contact PI